A. It is also indicated in over 50 countries for the adjunctive treatment of epilepsy and a range of neuropathic pain conditions. Viral culture, a direct immunofluorescence assay and polymerase chain reaction techniques were not done as these facilities were not available in our institute. Neurontin (gabapentin) is used to treat seizures and nerve pain caused by the herpes virus. Aim : This study was aimed to determine dose related efficacy and safety of gabapentin in reducing pain of acute herpetic neuralgia in geriatric patients. However, it is not known if GRALISE is safe and effective in people with seizure problems (epilepsy). Therefore, GRALISE should not be used in place of other gabapentin products.
FDA pregnancy category C. The use of the eHealthMe site and its content is at your own risk. It’s been working about 85% effectively. Not to be combined with insurance, great for drugs not covered by your plan. Only pain characteristics of control group patients were recorded. Other clinical details were not much stressed. Post therapy, the patients’ relief of pain was recorded in terms of pain relief reported by the patients in the following terminology.
Side effects to be cautious about are increased seizure frequency, fever, flu symptoms, irregular heartbeats, chest pain, trouble breathing, severe stomach pain, darkened urine, discoloured stools, jaundice, or severe skin rashes. 2) Poor relief. Take the missed dose as soon as you remember. The most common side effects of taking the generic drug Neurontin (Gabapentin) include exhaustion, fluid retention, nausea, vomiting, dizziness, hostility and ataxia or loss of muscle coordination. 5) Excellent relief. Do not switch from one form to the other without consulting your doctor.Tell your doctor if your condition does not improve or if it worsens. These effects may be worse if you take it with alcohol or certain medicines.
In these cases, your doctor may want to change the dose, or other precautions may be necessary. No history of an earlier attack of Varicella could be elicited from any of these patients. There were 6 patients in 15 to 20 years’ age group, 2 patients in 20 to 30 years’ age group 6 patients in 30 to 40 years’ age group, 8 patients in 40–50 years’ age group, 1 patient in 50-60 years’ age group and 2 patients in 60 to 70 years’ age group. Majority of patients were found to be 40 to 50 years’ age group. (Table no 1). You may or may not have a rash with these types of reactions. Only 3 patients presented with fewer discrete vesicular lesions though arranged in dermatomal pattern.
(Table no. You may need to use less and less before you stop the medication completely. The above findings are a useful pointer to the rationale of using a combination of acyclovir and single dose of 900 mg gabapentin which may attenuate acute pain in the present study. Capsaicin, lidocaine patches and nerve blocks can also be used in selected patients. In the present study, there were 25 patients of different age groups, maximum number of patients being present in the age group of 40-50 years. Matlin HJ, Foley MW. Accessed May 22, 2012.
(‘Multum’) is accurate, up-to-date, and complete, but no guarantee is made to that effect. Maximum number of patients are seen in thoracic group followed by trigeminal, cervical and lumbosacral group. In the present study, two young patients complained of mild pain with VAS of 2 and after therapy with acyclovir and gabapentin 900 mg single dose, the rash healed completely and there was excellent (100%) pain relief. They did not report any postherpetic neuralgia in a followup period of 3 and 5 months interval. Another group complained of VAS score of 4(30%) and 5(70%). This group consisted of 60% of the total patients and majority of the patients were 20 to 50 years age group. Following combination therapy with acyclovir and single dose gabapentin 900 mg, all the patients reported “good” pain relief with complete resolution of zoster rash with residual post inflammatory pigmentation.
Another group which consisted of 32% of total patients complained of severe pain at onset with VAS score of 8, all these patients were in the age of 40 to 65 years and one female patient was 70 years old. These patients displayed risk factors for development of postherpetic neuralgia. Your use of the content provided in this service indicates that you have read, understood and agree to the End-User License Agreement, which can be accessed by clicking on this link. One 45-year-old male patient reported for treatment after 72 hours of onset of rash. He developed secondary bacterial infection of the rash. If overdose is suspected, contact a poison control center or emergency room right away. This is not a complete list of all side effects that may occur.
On day 3, 300 milligrams (mg) three times a day. Among these two patients, one reported of moderate pain relief whereas the other reported of poor pain relief. This patient had secondary bacterial infection and he reported late to the hospital also. Among the 5 female patients in the present study, 3 patients had risk factors for postherpetic neuralgia i.e. female sex, age around 50 years and severe pain with VAS score of 8 but all of these patients reported good pain relief and did not report any postherpetic neuralgia on a followup period of 3 and 5 months interval. In the control group, among the 10 patients, 6 patients (60%) reported moderate pain relief, 1(10%) patient reported with good pain relief and 3 patients (30%) reported with poor pain relief and these 4 patients developed postherpetic neuralgia and all these patients were below 40 years of age. Though majority of the patients in the present study did not have risk factors for the development of postherpetic neuralgia, the findings revealed that a combination of acyclovir therapy with single dose of gabapentin 900 mg on the first day of starting of therapy plays a significant role in reduction of acute pain and also some pivotal role in prevention of postherpetic neuralgia as evidently seen from findings of control group where in 40% reported postherpetic neuralgia whereas only 8% of the study group reported postherpetic neuralgia.
CONCLUSION: From the present study, it may be conclusively said that gabapentin single dose in combination with acyclovir therapy plays a vital role in reduction of acute pain and prevention of postherpetic neuralgia. What should I avoid while taking Neurontin? REFERENCES: 1. David W Warenharm, Judith Breuer. Herpes zoster. British Medical Journal 2007;334(7605):1211-1215. 2.
Rhonda G Kost, Stephen E Starus. Postherpetic neuralgia pathogenesis treatment and prevention. The New England Journal of Medicine 1996;335(1):32-41. 3. Insinga RP, Itzler RF, Pelissier JM, et al. The incidence of herpes zoster in a United States administrative data base. J Gen inter Med 2005;20(8):748–753.
4. Gnann JW, Whitley RJ. Natural history and treatment of varicella–zoster in high risk populations. J Hosp infet 1991;18(Supple A):317-329. 5. Gnan JW, Whitley RJ. Clinical practice, Herpes zoster.
Do not double doses. 6. Dolin R, Reichman RC, Mazur NIH, et al. Conference Herpes zoster–varicella infection in immunosuppressed patients. Ann intern Med 1978;89(3):375-378. 7. Wall PD.
Neuropathic pain and injured nerve central mechanisms. Impotence. 8. Huff JC, Drucker JL, Chimmer A, et al. The effect of oral acyclovir on pain resolution in herpes zoster a reanalysis. Med Virol 1993;(Suppl 1):93-96. 9.
Esmann V, Gell JP, Kroon S, et al. Prednisolone does not prevent post–herpetic neuralgia. Lancet 1987:2(8551):126-129. 10. Whitley RJ, Weiss H, Gnann JW, et al. Acyclovir with or without prednisone for the treatment of herpes zoster; a randomized, placebo–controlled trial. The national institute of allergy and infectious diseases collaborative antiviral study group.
Ann intern Med 1996:125(5):376-383. 11. Van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia, a randomised controlled trial. Lancet 2006:367(9506):219-224. 12. Bowsher D.
The effects of pre-emptive treatment of post herpetic neuralgia with amitriptyline a randomized, double–blind placebo-controlled trial. J Pain Symptom Manage 1997:13(6):327-331. 13. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005;65(3):444-447. 14.
Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988;85(2A):79-83. 15. Gilden DH, Dueland AN, Cohrs R, et al. Preherpetic neuralgia. Neurology 1991;41(8):1215-1218.
16. Watson CPN. Post herpetic neuralgia. Neurol Clin 1998;7:231-248. 17. Watson CPN, Watt VR, Chipman M, et al. The prognosis with postherpetic neuralgia.
J Pain 1991;46(2):195-199. 18. Hope- Simpson RE. The nature of herpes zoster a long- term study and a new hypothesis. Proc R Soc Med 1965;58(1):9-20. 19. Burgeon CF, Burgeon JS, Baldridge GD.
The natural history of herpes zoster JAMA 1957:164(3):265-269. 20. Brown GR. Herpes zoster correlation of age, sex, distribution, neuralgia and associated disorders. South Med J 1976;69(5):576-578. 21. Wood M.
Understanding zoster-associated pain. In: How can the burden of zoster associated pain be reduced. Recommendations from the IHMF workshop Washington DC, Worthing United Kingdom PPS Europe 1993;3-11. 22. Epstein E. Treatment of zoster and post zoster neuralgia by the intralesional injection of triamcinolone: a computer analysis of 199 cases. International Journal of Dermatology 1976;35:762-769.
23. Balfour HH. Varicella zoster virus infectious in immunocompromised hosts: a review of the natural history and management. Am J Med 1988;85(2A):65-73. 24. Bennett GJ. Hypothesis on the pathogenesis of herpes zoster–associated pain.
Ann Neurol 1994;35(suppl):S38-41. 25. Devor M. Central changes meditating neuropathic pain. In: Dubner R, Gebbart GF, Bond MR eds. Proceedings of the Vth World congress on pain Amsterdam Elseviere Science 1988;114-128. 26.
Morton P, Thompson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989;102(863):93-95. 27. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia, a randomized double blind placebo controlled trial. Ann intern Med 1995;123(2):89-96.
28. Beutner KR, Freidmann DJ, Forszpaniak C, et al. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Anti Microb Agents Chemother 1995;39(7);1546-1553. 29. Huff JC, Bean B, Balfour HH, et al. Therapy of herpes zoster with oral acyclovir.
Am J Med 1988;85(Suppl 2A):84-88. 30. McKendrick MW, McGill JI, White JE, et al. Oral acyclovir in acute herpes zoster. Br Med J 1986;293(6561):1529-1532. 31. Wood MJ, Dworkin RH, Soong SJ, et al.
Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster a meta-analysis of placebo-controlled trials. Clin infect Dis 1996;22:341-347. 32. Dworkin RH, Perkins FM, Nagasako EM. Prospectus for the prevention of postherpetic neuralgia in herpes zoster patients. Clin J pain 2000;16(suppl2):S90-S100. 33.
Neurontin (package insert). New York, Pfizer Inc 2009. 34. Depomed Inc. Depomed announces US food and drug administration approval of Gralise (gabapentin) once daily tablets for treatment of post–herpetic neuralgia. Nasdaq 2011 Available at: http://investor.depomedine. comphonix.zhtml1?c= 9727 6&p=irol–news Article_pf&ID-1521435.
Accessed May 4, 2012. 35. Benjamin Beal, Tobias Moeller- Bertram, Jan M Schilling, et al. Gabapentin for once–daily treatment of postherpetic neuralgia: a review. Clinical Interventions in Aging 2012;7:249–255. 36. Bockbrader HN, Wesche D, Miller R, et al.
A compression of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin pharmacokinet 2010;49(10):661-669. 37. Drolet M, Brisson M, Schmader K, et al. Predictors of post herpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010;11(11):1211-1221. 38.
Johnson RW. Zoster–associated pain what is known, who is at risk and how can it be managed? Herpes 2007;14(Suppl 2):30-34. 39. Codere TJ, Katz J, Vaccarino AL, et al. Contribution of central neuro plasticity to pathological pain; review of clinical and experimental evidence. Pain 1993;52(3):258-285.
40. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998:280(12):1837-1842.